12:23:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-21 Bokslutskommuniké 2023
2023-11-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-07-03 Ordinarie utdelning IRRAS 0.00 SEK
2023-06-30 Årsstämma 2023
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-07-15 Extra Bolagsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 Ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
IRRAS är verksamt inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2019-10-15 15:00:00

-Company is co-hosting a Breakfast Symposium with the Neurocritical Care Society-

Stockholm, October 15, 2019 - IRRAS, a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, announced today its presence at the 17thNeurocritical Care Society's annual meeting, being held at the Vancouver Convention Centre, in Vancouver, British Columbia, Canada, on October 15-18, 2019.

IRRAS will be co-hosting a breakfast symposium with the Neurocritical Care Society that will address innovation in the sector with industry-leading key opinion leaders. Details are provided below.

IRRAS' Breakfast Symposium with Neurocritical Care Society
Title: "Bringing Needed Innovation to Neurocritical Care"
Date/Time: Thursday, October 17that 7:40 am
Location: Vancouver Convention Centre, Room 212-214

Conference attendees are encouraged to visit IRRAS' booth #221 to learn more about IRRAflow®, the world's first irrigating ventricular drainage system, as well as the Hummingbird Neuromonitoring product line.

For more information on this event, please visit the Media and Events tab on the IRRAS website at irras.com.

About IRRAS

IRRAS AB is a global healthcare company focused on delivering innovative medical technologies to our customers and their patients. IRRAS designs, develops and commercializes products that improve patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methods in neurocritical care. IRRAS markets and sells its products to hospitals worldwide through its direct sales organizations in the U.S. and select European countries and a network of distribution partners in other markets.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS AB (publ) is listed on Nasdaq First North Premier Growth Market in Stockholm, Sweden (ticker: IRRAS). Redeye AB is certified adviser of the company with email certifiedadviser@redeye.se orphone +46 8 121 576 90.
  

For more information, please contact:

USA
Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
ir@irras.com

Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com

    
The information was released for public disclosure, through the agency of the contact person above, on October 15, 2019 at 3:00 p.m. (CET).